The risk for adverse birth outcomes overall was not higher among HIV-infected pregnant women who received TDF-FTC-LPV/r than among those who received ZDV-3TC-LPV/r or TDF-FTC-ATV/r — contrary to previous research.
In the PROMISE trial (NEJM JW Infect Dis Dec 2016 and N Engl J Med 2016; 375:172), HIV-infected pregnant women in sub-Saharan Africa and India who were randomized to tenofovir-emtricitabine and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) were more than twice as likely as women randomized to zidovudine-lamivudine and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r) to have infants born very prematurely or at very low birth weight. To better understand the risk for adverse birth outcomes of TDF-FTC–based regimens during pregnancy, investigators analyzed data from two U.S.-based perinatal cohort studies.
A total of 4646 birth outcomes (including live births, stillbirths, and fetal deaths) occurred among 3847 women, 128 (2.8%) of them exposed to TDF-…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)